-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

To Consolidate or Not to Consolidate – The Role of Autologous Stem Cell Transplantation in MCL

Program: Education Program
Session: A Shifting Landscape: Treatment of MCL
Hematology Disease Topics & Pathways:
Combination therapy, Lymphomas, Non-Hodgkin lymphoma, Chemotherapy, Diseases, Treatment Considerations, Lymphoid Malignancies, Non-Biological therapies
Monday, December 9, 2024, 10:30 AM-11:45 AM

Martin Dreyling, MD

Dept. of Medicine, LMU University Hosptial München, Munich, Germany; Department of Medicine III, LMU University Hospital Munich, Munich, Germany

Disclosures: Dreyling: AbbVie, AstraZeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, F. Hoffmann-La Roche Ltd.: Membership on an entity's Board of Directors or advisory committees; AbbVie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Lilly, F. Hoffmann-La Roche Ltd.: Research Funding; AstraZeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, F. Hoffmann-La Roche Ltd.: Honoraria.

See more of: A Shifting Landscape: Treatment of MCL
See more of: Education Program
<< Previous Presentation | Next Presentation >>